Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: Influence of enalaprilat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 271, Issue 4 40-4, 1996, Pages

  Décarie, Anick ^a   Raymond, Philippe ^a   Gervais, Nicole ^a   Couture, Réjean ^a   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

angiotensin converting enzyme inhibitor; kininase I; kininase II

Indexed keywords

ARGININE CARBOXYPEPTIDASE; BRADYKININ; BRADYKININ[1-8]; CITRATE SODIUM; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; MEMBRANE METALLOENDOPEPTIDASE; THROMBIN INHIBITOR;

ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOG; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HALF LIFE TIME; HUMAN; HYDROLYSIS; IMMUNOREACTIVITY; KINETICS; METABOLISM; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SERUM; SPECIES DIFFERENCE;

EID: 33750831320     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1996.271.4.h1340     Document Type: Article

References (30)

1. Bhoola, K. D., C. D. Figueroa, and K. Worthy. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44: 1-80, 1992.
2. 1 receptor. Br. J. Pharmacol. 108: 318-322, 1993.
3. Décarie, A., G. Drapeau, J. Closset, R. Couture, and A. Adam. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 15: 511-518, 1994.
4. 9]BK (Abstract). In: Kinins 1995. Denver, CO: Fourteen International Symposium on Kinins, 10-15 September, 1995.
5. Dorer, F. E., J. R. Kahn, K. E. Lentz, M. Levine, and L. T. Skeggs. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ. Res. 34: 824-827, 1974.
6. Drapeau, G., A. Chow, and P. E. Ward. Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N. Peptides 12: 631-638, 1991.
7. Erdös, E. G. Some old and some new ideas on kinin metabolism. J. Cardiovasc. Pharmacol. 15, Suppl. 6: S20-S24, 1990.
8. Ferreira, S. H., and J. R. Vane. The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br. J. Pharmacol. Chemother. 30: 417-424, 1967.
9. Inokuchi, J.-I., and A. Nagamatsu. Tripeptidyl carboxypeptidase activity of kininase II (angiotensin-converting enzyme). Biochim. Biophys. Acta 662: 300-307, 1981.
10. Ishida, H., A. G. Scicli, and O. A. Carretero. Contributions of various rat plasma peptidases to kinin hydrolysis. J. Pharmacol. Exp. Ther. 251: 817-820, 1989.
11. Johnson, A. R., J. J. Coalson, J. Ashton, M. Larumbide, and E. G. Erdös. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin converting enzyme. Am. Rev. Respir. Dis. 132: 1262-1267, 1985.
12. 2Cl a selective affinity label for thrombin. Thrombin Res. 14: 969-973, 1979.
13. Kinoshita, A., H. Urata, M. Bumpus, and A. Husain. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ. Res. 73: 50-60, 1993.
14. Linz, W., G. Wiemer, P. Gohlke, T. Unger, and B. A. Schölkens. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47: 25-49, 1995.
15. Majima, M., C. Shima, M. Saito, Y. Kuribayashi, M. Katori, and T. Aoyagi. Prostatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine. Eur. J. Pharmacol. 232: 181-191, 1993.
16. 1 receptors: a review. Immunopharmacology 30: 1-26, 1995.
17. 9]BK in plasma. Can. J. Physiol. Pharmacol. 59: 131-138, 1981.
18. McCarthy, D. A., D. E. Potter, and E. D. Nicolaides. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J. Pharmacol. Exp. Ther. 148: 117-122, 1965.
19. Mirgorodskaya, O. A., and A. A. Shevchenko. Bradykinin degradation pathways in human blood plasma. FEBS Lett. 307: 263-266, 1992.
20. Moore, J. W., and R. G. Pearson. Complex reactions. In. Kinetics and Mechanism (3rd ed.), edited by J. W. Moore and R. G. Pearson. New York: Wiley, 1981, p. 284-296.
21. 2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br. J. Pharmacol 110: 71-76, 1993.
22. Plummer, T. H., Jr., and M. Y. Hurwitz. Human plasma carboxypeptidase N: isolation and characterization. J. Biochem. Chem. 253: 3907-3912, 1978.
23. 9-BK using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J. Immunol. Meth. 180: 247-257, 1995.
24. Regoli, D., and J. Barabé. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32: 1-46, 1980.
25. Ryan, J. W., P. Berryer, A. Y. K. Chung, and D. H. Sheffy. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J. Pharmacol. Exp. Ther. 269: 941-947, 1994.
26. Saameli, K., and T. K. A. B. Eskes. Bradykinin and cardiovascular system: estimation of half-life. Am. J. Physiol. 203: 261-265, 1962.
27. Scicli, A. G. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension Dallas 23: 419-421, 1994.
28. 9]-bradykinin by angiotensin converting enzyme. Biochem. Pharmacol. 35: 1951-1956, 1986.
29. Sheikh, I. A., and A. P. Kaplan. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B and N. Biochem. Pharmacol. 35: 1957-1963, 1986.
30. Ward, P. E. Metabolism of bradykinin, and bradykinin analogs. In: Bradykinin Antagonists. Basic and Clinical Research, edited by R. M. Burch. New York: Marcel Dekker, 1991, p. 147-170.